Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Minerva Neurosciences, Inc - Common Stock (NQ:NERV)

4.650 -0.040 (-0.85%)
Streaming Delayed Price Updated: 1:27 PM EDT, Sep 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Minerva Neurosciences, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy 
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Announces Leadership Transition
Jim O’Connor joins as Chief Business Officer and General Counsel 
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 
From Minerva Neurosciences, Inc
Via GlobeNewswire
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst ↗
Shares surged 141% to $6.41, marking their highest level since February 2024, after Minerva secured up to $200 million in financing led by top healthcare investors. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Minerva Stock Rises After Securing $200M for Schizophrenia Drug Trial ↗
Minerva Neurosciences Inc (NASDAQ:NERV) shares are climbing Tuesday after the company announced up to $200 million in funding to support development of roluperidone for schizophrenia. 
Via Benzinga
News headline image
These stocks are the most active in today's session ↗
Let's dive into the action on the US markets on Tuesday. Here are the most active stocks that are driving the market today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
US Stocks Mixed; Coca-Cola Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
These stocks that are showing activity before the opening bell on Tuesday. ↗
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Unusual volume stocks are being observed in Wednesday's session. ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
Top movers in Wednesday's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.